Active Biotech AB

Type: Company
Name: Active Biotech AB
Nationality: Sweden
Web Address: http://activebiotech.com/
Fact Sheet: Fact Sheet for Active Biotech AB
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Cantargia AB: Cantargia's Share Issue of 20 MSEK Fully Subscribed

By a News Reporter-Staff News Editor at Clinical Trials Week -- The completed share issue in Cantargia AB , directed to the shareholders in Lund University Bioscience AB , were fully subscribed. The share issue raises approximately 20 MSEK for Cantargia. ... [Published HispanicBusiness.com - Jul 16 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 3 reports

Cantargia’s share issue of 20 MSEK fully subscribed

The completed share issue in Cantargia AB , directed to the shareholders in Lund University Bioscience AB , were fully subscribed. The share issue raises approximately 20 MSEK for Cantargia. Cantargia develops a unique pharmaceutical for leukemia, in ... [Published HispanicBusiness.com - Jul 09 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

Updated Information on Prostate Cancer Drugs: Enzalutamide, Orteronel, and Cixutumumab

Treating Metastatic Castration-Resistant Prostate CancerEnzalutamide added to androgen-deprivation therapy provides clinically meaningful benefits to men with metastatic castration-resistant prostate cancer.—Andrew J. Armstrong, MD, ScM, FACPThree separate ... [Published The ASCO Post - Jun 25 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 1 reports

Cantargia gears up with new CEO and substantial capital injection

Cantargia, a private biopharmaceutical company developing therapeutics for the treatment of leukemia, announces that Dr. Göran Forsberg will take over the CEO position Furthermore, the company has decided to issue new shares corresponding to 20 MSEK.Cantargia ... [Published CisionWire - English - Jun 17 2014]
First reported May 26 2014 - Updated May 26 2014 - 1 reports

EMA's CHMP rejects approval of multiple sclerosis drug Nerventra

European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rejected the development of Nerventra (Laquinimod) for the treatment of relapsing-remitting multiple sclerosis (RRMS) by Israel-based Teva Pharmaceutical and Swedish ... [Published PBR - News - May 26 2014]
First reported May 23 2014 - Updated May 23 2014 - 2 reports

Teva and Active Biotech to Continue with the Development of Nerventra® (Laquinimod) for Multiple Sclerosis Following Confirmation of CHMP Opinion

JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) announced today that the Committee for Medicinal Products for Human Use (CHMP) confirmed its January 23, 2014 opinion ... [Published Business Wire Science: Science News - May 23 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Active Biotech schedules AGM

Active Biotech AB will hold its annual general meeting at Elite Hotel Ideon, Scheelev$¤gen 27 in Lund, Sweden, on 15 May at 5 p.m.Story provided by StockMarketWire.com ... [Published TrustNet - Apr 14 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 2 reports

Annual Report 2013 Active Biotech AB publ

Active Biotech 's Annual Report 2013 (in Swedish) is now available for download at www.activebiotech.com . The English version will be available within short.Related Biotechnology, Pharmaceutical and Healthcare NewsThe Annual Report will only be digitally ... [Published BioPortfolio - Apr 07 2014]
First reported Feb 27 2014 - Updated Feb 27 2014 - 1 reports

Multiple sclerosis drug in development: laquinimod

A new oral multiple sclerosis drug in development, Nerventra (laquinimod), appears to have modest effects on relapses but there is a possibility of long-term benefits, according to the newly-published results of the BRAVO trial (Vollmer and colleagues. ... [Published MSology - Feb 27 2014]
Entities: Laquinimod, Avonex, Placebo
First reported Feb 18 2014 - Updated Feb 18 2014 - 1 reports

Immunicum: Interim Report July - December 2013

Gothenburg, Sweden, 2014-02-18 08:59 CET (GLOBE NEWSWIRE) -- Second half of 2013 compared with the same period in 2012 The net loss for the period July 1 - December 31, 2013 amounted to - 5 583 KSEK, compared to - 2 177 KSEK for the same period in 2012. ... [Published GlobeNewswire - Feb 18 2014]
Entities: T-cells, Cancer, Kidney

Quotes

Lars H Bruzelius , the chairman of the main owner of Cantargia, Lund University Bioscience AB : "The company is, through the recruitment of Goran Forsberg as CEO, the reinforced board of directors since the beginning of 2014, and the completed share issue, well positioned to continue driving this unique pharmaceutical project forward."
More From BioPortfolio on "Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019"

More Content

All (42) | News (15) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (5) | Press Releases (16)
sort by: Date | Relevance
Cantargia AB: Cantargia's Share Issue of 20 MSE... [Published HispanicBusiness.com - Jul 16 2014]
Cantargia’s share issue of 20 MSEK fully subscr... [Published HispanicBusiness.com - Jul 09 2014]
Cantargia AB: Cantargia’s Share Issue of 20 MSE... [Published BusinessWeek - Jul 09 2014]
Cantargia AB: Cantargia's Share Issue of 20 MSE... [Published CNBC - Jul 09 2014]
Updated Information on Prostate Cancer Drugs: E... [Published The ASCO Post - Jun 25 2014]
Cantargia gears up with new CEO and substantial... [Published CisionWire - English - Jun 17 2014]
Active Biotech presents data on paquinimod at E... [Published GlobeNewswire: Acquisitions News - Jun 11 2014]
Active Biotech presents data on paquinimod at E... [Published GlobeNewswire: Acquisitions News - Jun 11 2014]
Active Biotech to Present at Jefferies 2014 Hea... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
Active Biotech to Present at Jefferies 2014 Hea... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
EMA's CHMP rejects approval of multiple scleros... [Published PBR - News - May 26 2014]
Teva and Active Biotech to continue with the de... [Published GlobeNewswire: Acquisitions News - May 23 2014]
Teva and Active Biotech to Continue with the De... [Published Business Wire Science: Science News - May 23 2014]
Teva and Active Biotech to Continue with the De... [Published Business Wire Health News - May 23 2014]
Annual General Meeting of Active Biotech AB [Published GlobeNewswire: Acquisitions News - May 16 2014]
Annual General Meeting of Active Biotech AB [Published GlobeNewswire: Acquisitions News - May 16 2014]
Active Biotech AB Interim report January - Marc... [Published GlobeNewswire: Acquisitions News - Apr 24 2014]
Active Biotech AB Interim report January - Marc... [Published GlobeNewswire: Acquisitions News - Apr 24 2014]
Active Biotech schedules AGM [Published TrustNet - Apr 14 2014]
Active Biotech - Notice of Annual General Meeti... [Published GlobeNewswire: Advertising News - Apr 14 2014]
Active Biotech - Notice of Annual General Meeti... [Published GlobeNewswire: Advertising News - Apr 14 2014]
Annual Report 2013 Active Biotech AB publ [Published BioPortfolio - Apr 07 2014]
Annual Report 2013 Active Biotech AB (publ) [Published GlobeNewswire: Advertising News - Apr 07 2014]
Annual Report 2013 Active Biotech AB (publ) [Published GlobeNewswire - Apr 07 2014]
Multiple sclerosis drug in development: laquinimod [Published MSology - Feb 27 2014]
Change in the clinical development program for ... [Published GlobeNewswire: Acquisitions News - Feb 19 2014]
Change in the clinical development program for ... [Published GlobeNewswire: Acquisitions News - Feb 19 2014]
Immunicum: Interim Report July - December 2013 [Published GlobeNewswire - Feb 18 2014]
Active Biotech AB Year-end report January - Dec... [Published GlobeNewswire: Advertising News - Feb 13 2014]
Active Biotech AB Year-end report January - Dec... [Published GlobeNewswire: Advertising News - Feb 13 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Cantargia gears up with new CEO and substantial... [Published CisionWire - English - Jun 17 2014]
Cantargia, a private biopharmaceutical company developing therapeutics for the treatment of leukemia, announces that Dr. Göran Forsberg will take over the CEO position Furthermore, the company has decided to issue new shares corresponding to 20 MSEK.Cantargia ...
EMA's CHMP rejects approval of multiple scleros... [Published PBR - News - May 26 2014]
European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rejected the development of Nerventra (Laquinimod) for the treatment of relapsing-remitting multiple sclerosis (RRMS) by Israel-based Teva Pharmaceutical and Swedish ...
Teva and Active Biotech to Continue with the De... [Published Business Wire Science: Science News - May 23 2014]
JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) announced today that the Committee for Medicinal Products for Human Use (CHMP) confirmed its January 23, 2014 opinion ...
Teva and Active Biotech to Continue with the De... [Published Business Wire Health News - May 23 2014]
JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) announced today that the Committee for Medicinal Products for Human Use (CHMP) confirmed its January 23, 2014 opinion ...
Multiple sclerosis drug in development: laquinimod [Published MSology - Feb 27 2014]
A new oral multiple sclerosis drug in development, Nerventra (laquinimod), appears to have modest effects on relapses but there is a possibility of long-term benefits, according to the newly-published results of the BRAVO trial (Vollmer and colleagues. ...
1 2

Press Releases

sort by: Date | Relevance
Active Biotech presents data on paquinimod at E... [Published GlobeNewswire: Acquisitions News - Jun 11 2014]
Active Biotech presents data on paquinimod at E... [Published GlobeNewswire: Acquisitions News - Jun 11 2014]
Active Biotech to Present at Jefferies 2014 Hea... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
Active Biotech to Present at Jefferies 2014 Hea... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
Teva and Active Biotech to continue with the de... [Published GlobeNewswire: Acquisitions News - May 23 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.